Q-omics provides the consensus-scored DENND10 profile across patient tissues and cancer cell-line models. DENND10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DENND10 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, DENND10 protein abundance shows 20,013 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where DENND10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND10 survival associations across molecular data types. DENND10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND10 RNA expression–survival associations across cancer types. High DENND10 expression shows unfavorable associations in ACC, UVM and LIHC, but favorable associations in LGG, KIRC and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DENND10 RNA expression.
This table summarizes DENND10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DENND10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND10 shows lower tumor expression in COAD, KIRC and KICH and higher tumor expression in LIHC, LUAD and LUSC. The LIHC box plot shows higher DENND10 RNA expression in tumor versus normal tissue (log2 FC = +1.033, t-test p < 0.001).
This table shows molecular features associated with DENND10 in patient tissues and cancer cell lines. In patient samples, DENND10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
